Drug Repurposing for the Treatment of Acute Myeloid Leukemia

Frontiers in Medicine - Switzerland
doi 10.3389/fmed.2017.00211
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Frontiers Media SA

Related search

Off-Target Based Drug Repurposing Opportunities for Tivantinib in Acute Myeloid Leukemia

Scientific Reports
Multidisciplinary
2019English

Molecular Emergence of Acute Myeloid Leukemia During Treatment for Acute Lymphoblastic Leukemia

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2001English

Advances in Treatment Formulations for Acute Myeloid Leukemia

Drug Discovery Today
Drug DiscoveryPharmacology
2018English

Repositioning of Bromocriptine for Treatment of Acute Myeloid Leukemia

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2016English

Oligonucleotide Aptamer-Drug Conjugates for Targeted Therapy of Acute Myeloid Leukemia

Biomaterials
Mechanics of MaterialsBiophysicsBiomaterialsBioengineeringCompositesNanoscienceNanotechnologyCeramics
2015English

FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2011English

Acute Myeloid Leukemia Drug Development in the Post‐Venetoclax Era

American Journal of Hematology
Hematology
2019English

Treatment of Childhood Acute Myeloid Leukemia in Bulgaria

Folia Medica
Medicine
2018English

Acute Myeloid Leukemia

JAMA - Journal of the American Medical Association
Medicine
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy